Pen kit box
From $173.60
- What you get
- The reusable pen, 1 dual-chamber vial, 12 needles and a booklet, in the VETUD box
- BAC water
- Included, in the cartridge
3 / 5
VTD-RT · Weight management
Triple GIP, GLP-1 and glucagon receptor agonist in clinical metabolic research.
$173.60
Regular price $217.00
20% offPen kit box · 10 mg
Free standard shipping on orders over $200
Choose a format
Amount
In the box · Pen kit box
VETUD box with the reusable pen body, 1 dual-chamber vial (lyophilized peptide in one chamber, bacteriostatic water in the other), 12 disposable needles and an instruction booklet
All Products listed on this site are for research purposes only. All products sold on this website are intended for research and identification purposes only. These products are not intended for human dosing, injection, or ingestion.
An experimental “triple” hormone medicine that has produced some of the largest weight losses ever seen in a drug trial.
Not approved anywhere yet. Eli Lilly has reported positive results from its large phase 3 trials and plans to apply for US approval by early 2027.
Retatrutide is an experimental medicine made by Eli Lilly. It acts on three hormone targets at once: GLP-1, GIP and glucagon.
GLP-1 and GIP reduce appetite and help control blood sugar. Glucagon is thought to make the body burn more energy, including fat stored in the liver. Together they work on appetite and on energy use at the same time.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial ↗
Jastreboff et al. · New England Journal of Medicine · 2023
TRIUMPH-1: phase 3 retatrutide topline results ↗
Eli Lilly and Company · original sponsor announcement · May 21, 2026
TRIUMPH-2 and TRIUMPH-3: phase 3 retatrutide topline results ↗
Eli Lilly and Company · original sponsor announcement · July 23, 2026
Scientific background concerns the named molecule. Batch composition and analytical results must be established from the product documentation. All products sold on this website are intended for research and identification purposes only. These products are not intended for human dosing, injection, or ingestion.
SKUVTD-RT-VIAL-10MG, VTD-RT-VIAL-20MG, VTD-RT-PEN-10MG, VTD-RT-VIAL-40MG, VTD-RT-BOX-10MG, VTD-RT-PEN-20MG, VTD-RT-BOX-20MG, VTD-RT-PEN-40MG, VTD-RT-BOX-40MG
Follow the manufacturer's batch-specific storage temperature and conditions.
Keep in original packaging, away from direct sunlight and excess heat.
Refer to the lot-specific expiry date and stability documentation. Shelf life should not be inferred from the product name alone.
For solvent compatibility or preparation specifications, request the manufacturer’s batch documentation. Research protocols should be established by qualified laboratory personnel.
Every product comes three ways. It's the same peptide and the same amounts; what changes is the packaging, what's included and the price. Start with the pen kit box, which has the reusable pen, then refill it with dual-chamber vials.
From $173.60
From $141.60
From $61.60
The freeze-dried peptide and the bacteriostatic (BAC) water sit in separate chambers, divided by a rubber stopper. They stay apart until the cartridge is used.
The pen kit box has the reusable pen body with a dual-chamber vial, 12 disposable needles and a booklet. The drive, dial and indicator window stay with the pen: when a cartridge is empty, fit a new dual-chamber vial.
Choose the vial if you already have bacteriostatic water and your own lab supplies. It's the lowest price for the same amount.
Related
Small-molecule NNMT inhibitor studied in cell metabolism research.
Pen kit box / Dual-chamber vial / Vial · 10 mg / 50 mg
From$48.00regular price $60.00
AvailableAll Products listed on this site are for research purposes only
Fragment of human growth hormone studied in fat-metabolism research.
Pen kit box / Dual-chamber vial / Vial · 5 mg / 10 mg
From$33.60regular price $42.00
AvailableAll Products listed on this site are for research purposes only
Long-acting copy of the gut hormone GLP-1, studied in weight and diabetes research.
Pen kit box / Dual-chamber vial / Vial · 10 mg / 20 mg / 40 mg
From$50.40regular price $63.00
AvailableAll Products listed on this site are for research purposes only
Education
Plain-language guides, news about new studies and selected videos from doctors and researchers. Published studies are about the named compound; they don't establish the safety or performance of this research product.
Weight management
LY3437943, often called “triple G”
An experimental “triple” hormone medicine that has produced some of the largest weight losses ever seen in a drug trial.
StudyWeight management
The experimental peptide combines GLP-1, GIP, amylin and calcitonin activity. Here is what the original research can tell us about weight loss.
StudyWeight management
New phase 3 results show strong weight loss in people with type 2 diabetes or heart disease. Lilly plans to apply for US approval by early 2027.
StudyWeight management
Eli Lilly’s experimental “triple” hormone medicine helped people lose more than a quarter of their body weight on the top dose.
Dr Brad Stanfield
A physician reviews retatrutide results. Read the linked trial reports for the population, follow-up and analysis used.
Brad Stanfield, MBChB · general practitioner
Discusses the compound
Discusses Retatrutide or its clinical context. Read the original studies linked here for the exact formulation, population and outcomes.
Dr Brad Stanfield
A GP reads the retatrutide trial data and what it does and doesn’t show.
Brad Stanfield, MBChB, general practitioner
Discusses the compound
Discusses Retatrutide or its clinical context. Read the original studies linked here for the exact formulation, population and outcomes.
Ohio State Wexner Medical Center
A hospital explainer of GLP-1 signalling, appetite and blood-sugar regulation.
Allison L. Rhodes, MD · obesity medicine
Related biology
Background on GLP-1 signalling for understanding Retatrutide. It does not demonstrate benefits of this compound or formulation.